NCT05694819 2026-04-08
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
National Cancer Center Hospital East
Phase 2 Completed
Clinical Trials
6 trialsNCT05526248 2026-03-11
ARAMON
Bayer
Phase 2 Completed
NCT05171387 2025-06-22
Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer
Bayer
Phase 2 Completed
NCT03314324 2025-04-17
ODENZA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT03383679 2022-11-21
START
UNICANCER
Phase 2 Completed
NCT01429064 2017-02-20
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Orion Corporation, Orion Pharma
Phase 2 Completed